Patent Prosecution
Overview
Technology and the laws meant to protect it—especially the patent laws—are always changing. But the law is not always in sync with technological developments. Companies seeking protection for their state-of-the-art innovations need counsel who not only know what the law is, but where it is likely headed. Crowell & Moring’s team of experienced patent professionals have the experience, knowledge, and judgment to provide such guidance to our clients.
Insights
Client Alert | 4 min read | 04.01.25
Hatch-Waxman PTE for Reissue Patents Should Be Calculated From the Original Patent’s Issue Date
On March 13, 2025, the United States Court of Appeals for the Federal Circuit issued a decision about Patent Term Extensions (PTEs) under the Hatch-Waxman Act for reissue patents. In Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254), the Court confirmed that the PTE provision under 35 U.S.C. § 156 refers to the original patent’s issue date, not the reissue patent’s issue date. Thus, the issue date of the original patent should be used when calculating the extension period.
Client Alert | 4 min read | 03.27.25
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
Client Alert | 12 min read | 03.19.25
Right To Repair – A Growing Trend for States Creating Compliance Challenges for Manufacturers
Insights
EV charging stations & connectors: the importance of design patents
|11.15.24
EV Design & Manufacturing
New Momentum For Bill Limiting Contracts With Chinese Biotech Cos.
|07.21.24
Foreign Investment Watch
Professionals
Insights
Client Alert | 4 min read | 04.01.25
Hatch-Waxman PTE for Reissue Patents Should Be Calculated From the Original Patent’s Issue Date
On March 13, 2025, the United States Court of Appeals for the Federal Circuit issued a decision about Patent Term Extensions (PTEs) under the Hatch-Waxman Act for reissue patents. In Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254), the Court confirmed that the PTE provision under 35 U.S.C. § 156 refers to the original patent’s issue date, not the reissue patent’s issue date. Thus, the issue date of the original patent should be used when calculating the extension period.
Client Alert | 4 min read | 03.27.25
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
Client Alert | 12 min read | 03.19.25
Right To Repair – A Growing Trend for States Creating Compliance Challenges for Manufacturers
Insights
Client Alert | 4 min read | 04.01.25
Hatch-Waxman PTE for Reissue Patents Should Be Calculated From the Original Patent’s Issue Date
On March 13, 2025, the United States Court of Appeals for the Federal Circuit issued a decision about Patent Term Extensions (PTEs) under the Hatch-Waxman Act for reissue patents. In Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (No. 2023-2254), the Court confirmed that the PTE provision under 35 U.S.C. § 156 refers to the original patent’s issue date, not the reissue patent’s issue date. Thus, the issue date of the original patent should be used when calculating the extension period.
Client Alert | 4 min read | 03.27.25
Client Alert | 4 min read | 03.24.25
USPTO Finds Claims of Two of Moderna’s mRNA Patents Unpatentable: What’s Next in the Vaccine Wars?
Client Alert | 12 min read | 03.19.25
Right To Repair – A Growing Trend for States Creating Compliance Challenges for Manufacturers